Oligonucleotide Therapeutics Market, By Oligonucleotide Class, By Application, By Delivery System, By End User, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

Description

Oligonucleotide Therapeutics Market size was valued at US$ 7,180.2 Million in 2025, expanding at a CAGR of 20.3% from 2026 to 2033.

Oligonucleotide therapeutics represent a class of chemically engineered DNA or RNA-based drugs that modulate gene expression or RNA function through specific molecular interactions. The market includes antisense oligonucleotides, small interfering RNA, microRNA-based pharmaceuticals, aptamers, ribozymes, immunostimulatory oligonucleotides, conjugates, and related innovative technologies, as well as accompanying synthesis, production, analysis, and services. The products are intended for the treatment of a wide range of diseases, including orphan, neurologic, metabolic, cardiovascular, renal, infectious diseases, and cancer.

A growing emphasis is placed on design innovations such as backbone and sugar modifications, sequence design, conjugation strategies, control of impurities, and analytical validation for commercial development. In 2025, the FDA approved 46 new drugs, reflecting increased acceptance in the broader regulatory environment for more varied and complex therapeutic approaches. Overall, the field of oligonucleotide therapeutics is transitioning from a phase of technology development to one of generating more predictable drug category with specific mechanisms of action for a variety of disease targets.

Oligonucleotide Therapeutics Market- Market Dynamics

Advances in Delivery Are Expanding the Reach of Gene-Silencing Therapies

Innovations in delivery methodologies are now enabling oligonucleotide therapies to target previously inaccessible tissues and increase the drugs' therapeutic efficacy. Chemical modifications, ligand-conjugated polymers, backbone alterations, and other cutting-edge technologies can improve oligonucleotides' pharmacokinetic properties, cellular entry mechanisms, tissue distribution, and persistence, thereby increasing their clinical performance and range of applications. The most critical applications for such delivery advancements include neurological, renal, metabolic, and cardiovascular indications. During the year 2025, the FDA approved three different oligonucleotide therapies: fitusiran, donidalorsen, and plozasiran, confirming the regulators' ongoing interest in the medicinal products. From this perspective, an expanded number of modalities across diverse mechanisms are required to harness the therapeutic potential of sequence-specific drugs fully and further address a wide range of medical conditions.

Oligonucleotide Therapeutics Market- Geographical Insights

North America remains a key development region for oligonucleotide therapeutics, driven by the presence of biotech ecosystems, translational clinical expertise, regulatory and academic capabilities, and advanced manufacturing and supply networks. The U.S. drug development landscape offers access to RNA-focused developers, CDMOs, analytical and research organizations, and investors who can help navigate the challenges of target discovery and bring the molecule through clinical trials, as well as a large clinical trials infrastructure. According to ClinicalTrials.gov, in 2025, there were 42,966 studies first posted during the year across indications. For oligonucleotide developers, the well-established U.S. clinical and translational ecosystem can provide critical support and shorten the learning curve of such complex R&D projects.

Europe is an important region for oligonucleotide development, with a regulatory environment that fosters work on complex molecules while also providing critical insights into rare diseases and diverse mechanisms of genetic diseases. The European Medicines Agency (EMA) has published guidance on various aspects of oligonucleotide therapeutics, including synthesis, conjugation, characterization, analytical control, and quality requirements, supporting the development of such complex molecules. The regulatory environment in Europe fosters work on a wide range of genetic disease areas-from rare diseases and neuromuscular disorders to ophthalmology and metabolic diseases. In 2025, the EMA granted orphan designation to an antisense oligonucleotide targeting ABCA4 pre-mRNA for the treatment of inherited retinal dystrophy, demonstrating Europe's regulatory and scientific commitment to the field.

Oligonucleotide Therapeutics Market- Competitive Landscape:

Competition in the oligonucleotide therapeutics sector is intensifying, with industry players focusing on the differentiation of their platforms, the breadth of delivery approaches, the execution of trials, and control over manufacturing to obtain an advantage. Alnylam is a major player in the RNA interference space; Ionis has broad antisense experience, and Arrowhead, Avidity, and ProQR have diversified approaches to delivery, conjugation, and RNA modulation. Control over manufacturing is also a critical success factor due to the complexity of sequence design, impurities, conjugation, and analytical release. In 2025, Alnylam expects to have three Phase III programs, which shows that the company continues to advance its pipeline. Thus, for the most part, competition is driven by the combination of successful delivery vehicles, development, and manufacturing expertise.

Recent Developments:

In December 2025, Alnylam Pharmaceuticals announced the expansion of its RNAi manufacturing infrastructure in Norton, Massachusetts. With this new project, Alnylam aims to increase the production capacities of siRNA-based medications by enhancing the organization's core competencies in drug manufacturing.

In October 2025, ProQR Therapeutics announced the first European regulatory approval to advance in the clinical trial stage of its investigational RNA-editing therapeutic candidate, AX-0810. The company's intention is to target the NTCP gene for the treatment of cholestatic diseases using an innovative RNA-editing approach. This new development allows the company to initiate a Phase 1 study of the drug category.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Ionis Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Biogen Inc.
Novartis AG
Arrowhead Pharmaceuticals, Inc.
Roche / Genentech
Astellas Pharma Inc.
Nippon Shinyaku Co., Ltd.
Amgen Inc.
Regeneron Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc.
Moderna, Inc.
Wave Life Sciences Ltd.
Arcturus Therapeutics Holdings Inc.
Avidity Biosciences, Inc.
Silence Therapeutics plc
Nitto Denko Corporation / Nitto Denko Avecia
Stoke Therapeutics, Inc.
Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY OLIGONUCLEOTIDE CLASS- MARKET ANALYSIS, 2020 - 2033

Antisense Oligonucleotides (ASOs)
Small Interfering RNA (siRNA / RNAi)
microRNA (miRNA)
Aptamers
CpG Oligonucleotides
Ribozymes
Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

Neurological Disorders
Cardiometabolic Disorders
Oncology
Infectious Diseases
Kidney / Renal Diseases
Ophthalmology
Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY DELIVERY SYSTEM- MARKET ANALYSIS, 2020 - 2033

Lipid Nanoparticles (LNPs)
GalNAc Conjugates
Peptide Conjugates
Polymer-Based Delivery Systems
Other Conjugates / Delivery Systems

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

Pharmaceutical & Biotechnology Companies
Hospitals & Specialty Clinics
Academic & Research Institutes
Contract Research Organizations (CROs)
Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

Subcutaneous
Intravenous
Intrathecal
Intramuscular
Others

GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Denmark
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Taiwan
Vietnam
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Iran
Qatar
Rest of MEA

Product Code: ANV7311

1. Oligonucleotide Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
2.2. Competitive Insights

3. Oligonucleotide Therapeutics Key Market Trends

3.1. Oligonucleotide Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Oligonucleotide Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Oligonucleotide Therapeutics Market Opportunities
3.4. Oligonucleotide Therapeutics Market Future Trends

4. Oligonucleotide Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Oligonucleotide Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Oligonucleotide Therapeutics Market Landscape

6.1. Oligonucleotide Therapeutics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Oligonucleotide Therapeutics Market - By Oligonucleotide Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Oligonucleotide Class, 2025 & 2033 (%)
- 7.1.2. Antisense Oligonucleotides (ASOs)
- 7.1.3. Small Interfering RNA (siRNA / RNAi)
- 7.1.4. microRNA (miRNA)
- 7.1.5. Aptamers
- 7.1.6. CpG Oligonucleotides
- 7.1.7. Ribozymes
- 7.1.8. Others

8. Oligonucleotide Therapeutics Market - By Application

8.1. Overview
- 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
- 8.1.2. Neurological Disorders
- 8.1.3. Cardiometabolic Disorders
- 8.1.4. Oncology
- 8.1.5. Infectious Diseases
- 8.1.6. Kidney / Renal Diseases
- 8.1.7. Ophthalmology
- 8.1.8. Others

9. Oligonucleotide Therapeutics Market - By Delivery System

9.1. Overview
- 9.1.1. Segment Share Analysis, By Delivery System, 2025 & 2033 (%)
- 9.1.2. Lipid Nanoparticles (LNPs)
- 9.1.3. GalNAc Conjugates
- 9.1.4. Peptide Conjugates
- 9.1.5. Polymer-Based Delivery Systems
- 9.1.6. Other Conjugates / Delivery Systems

10. Oligonucleotide Therapeutics Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 10.1.2. Pharmaceutical & Biotechnology Companies
- 10.1.3. Hospitals & Specialty Clinics
- 10.1.4. Academic & Research Institutes
- 10.1.5. Contract Research Organizations (CROs)
- 10.1.6. Others

11. Oligonucleotide Therapeutics Market - By Route of Administration

11.1. Overview
- 11.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 11.1.2. Subcutaneous
- 11.1.3. Intravenous
- 11.1.4. Intrathecal
- 11.1.5. Intramuscular
- 11.1.6. Others

12. Oligonucleotide Therapeutics Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Oligonucleotide Therapeutics Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Oligonucleotide Therapeutics Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.18. Denmark
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.18.3. Denmark Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.18.4. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.18.5. Denmark Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.18.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.18.7. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.19. Rest of Europe
  - 12.3.19.1. Overview
  - 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.19.3. Rest of the Europe Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.3.19.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.3.19.5. Rest of the Europe Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.3.19.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.3.19.7. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Oligonucleotide Therapeutics Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.17. Taiwan
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.17.3. Taiwan Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.17.4. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.17.5. Taiwan Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.17.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.17.7. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.18. Vietnam
  - 12.4.18.1. Overview
  - 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.18.3. Vietnam Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.18.4. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.18.5. Vietnam Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.18.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.18.7. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.19. Rest of APAC
  - 12.4.19.1. Overview
  - 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.19.3. Rest of APAC Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.4.19.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.4.19.5. Rest of APAC Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.4.19.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.4.19.7. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Oligonucleotide Therapeutics Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Oligonucleotide Therapeutics Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.15. Iran
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.15.3. Iran Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.15.4. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.15.5. Iran Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.15.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.15.7. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.16. Qatar
  - 12.6.16.1. Overview
  - 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.16.3. Qatar Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.16.4. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.16.5. Qatar Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.16.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.16.7. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.17. Rest of MEA
  - 12.6.17.1. Overview
  - 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.17.3. Rest of MEA Market Size and Forecast, By Oligonucleotide Class, 2020 - 2033 (US$ Million)
  - 12.6.17.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
  - 12.6.17.5. Rest of MEA Market Size and Forecast, By Delivery System, 2020 - 2033 (US$ Million)
  - 12.6.17.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  - 12.6.17.7. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Oligonucleotide Therapeutics Industry

13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. Ionis Pharmaceuticals, Inc.
- 13.2.2. Alnylam Pharmaceuticals, Inc.
- 13.2.3. Sarepta Therapeutics, Inc.
- 13.2.4. Biogen Inc.
- 13.2.5. Novartis AG
- 13.2.6. Arrowhead Pharmaceuticals, Inc.
- 13.2.7. Roche / Genentech
- 13.2.8. Astellas Pharma Inc.
- 13.2.9. Nippon Shinyaku Co., Ltd.
- 13.2.10. Amgen Inc.
- 13.2.11. Regeneron Pharmaceuticals, Inc.
- 13.2.12. BioMarin Pharmaceutical Inc.
- 13.2.13. Moderna, Inc.
- 13.2.14. Wave Life Sciences Ltd.
- 13.2.15. Arcturus Therapeutics Holdings Inc.
- 13.2.16. Avidity Biosciences, Inc.
- 13.2.17. Silence Therapeutics plc
- 13.2.18. Nitto Denko Corporation / Nitto Denko Avecia
- 13.2.19. Stoke Therapeutics, Inc.
- 13.2.20. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us